8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Whole Body / General595 citations

Urnukhsaikhan E, Mishig-Ochir T, Kim S-C, Park J-K, Seo Y-K

Bioeffects Seen

Authors not listed · 2017

Share:

This pharmaceutical study of myasthenia gravis treatment contains no EMF research and appears misclassified in EMF databases.

Plain English Summary

Summary written for general audiences

This pharmaceutical study tested eculizumab, a complement inhibitor drug, in 125 patients with severe myasthenia gravis (a neuromuscular disease). The primary endpoint showed no statistically significant improvement compared to placebo, though secondary analyses suggested potential benefits. The study highlights challenges in clinical trial design for rare neurological conditions.

Why This Matters

This study appears to be misclassified in our EMF database, as it examines a pharmaceutical intervention for myasthenia gravis rather than electromagnetic field exposure effects. The research focuses on complement system inhibition using eculizumab, with no EMF component whatsoever. This highlights the importance of proper study categorization in health databases. While the research itself is valuable for understanding autoimmune neuromuscular conditions, it provides no insights into EMF health effects or exposure risks that would be relevant to our readers concerned about electromagnetic radiation from wireless devices, power lines, or other EMF sources.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Unknown (2017). Urnukhsaikhan E, Mishig-Ochir T, Kim S-C, Park J-K, Seo Y-K.
Show BibTeX
@article{urnukhsaikhan_e_mishig_ochir_t_kim_s_c_park_j_k_seo_y_k_ce4575,
  author = {Unknown},
  title = {Urnukhsaikhan E, Mishig-Ochir T, Kim S-C, Park J-K, Seo Y-K},
  year = {2017},
  doi = {10.1016/S1474-4422(17)30369-1},
  
}
DOI: 10.1016/S1474-4422(17)30369-1PubMed: 29066163

Quick Questions About This Study

This appears to be a database classification error. The study examines eculizumab pharmaceutical treatment for myasthenia gravis with no electromagnetic field component, making it irrelevant to EMF health research.
No, eculizumab is an intravenous pharmaceutical drug that inhibits complement proteins. The treatment involves no electromagnetic field exposure or EMF-related interventions of any kind.
While both conditions can involve neurological symptoms, myasthenia gravis is an autoimmune disease affecting neuromuscular transmission, distinct from reported electromagnetic hypersensitivity symptoms. Proper medical evaluation distinguishes between them.
The REGAIN trial studied only pharmaceutical intervention with no EMF exposure component. It found no significant difference between drug and placebo for the primary endpoint in myasthenia gravis patients.
No direct relationship exists. Complement inhibitors target immune system proteins, while EMF research examines electromagnetic radiation effects. This study's inclusion in EMF databases appears to be an indexing error.